Mainstream

M&A Snapshot: Novartis to buy Tourmaline Bio for $1.4B, citing promise of heart drug pacibekitug

M&A Snapshot: Novartis to buy Tourmaline Bio for $1.4B, citing promise of heart drug pacibekitug

Post Contentnvs, trmlRead More

You might also be interested in reading RADEX MARKETS, B2Prime, Tickmill, and More: Executive Moves of the Week.

September 9, 2025
In Mainstream